Aquestive Therapeutics, Inc.
AQST · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $329 | $277 | $325 |
| - Cash | $129 | $61 | $69 | $72 |
| + Debt | $120 | $126 | $39 | $38 |
| Enterprise Value | – | $394 | $247 | $291 |
| Revenue | $13 | $10 | $9 | $12 |
| % Growth | 28% | 14.7% | -26.5% | – |
| Gross Profit | $8 | $5 | $5 | $7 |
| % Margin | 64.8% | 54.4% | 58.1% | 61.9% |
| EBITDA | -$11 | -$9 | -$16 | -$13 |
| % Margin | -86.2% | -91.3% | -180.8% | -107% |
| Net Income | -$15 | -$14 | -$23 | -$17 |
| % Margin | -120.6% | -135.4% | -263% | -143.7% |
| EPS Diluted | -0.14 | -0.14 | -0.24 | -0.19 |
| % Growth | 0% | 41.7% | -26.3% | – |
| Operating Cash Flow | -$13 | -$8 | -$23 | -$6 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$13 | -$8 | -$24 | -$7 |